<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><div><div><p>Add <img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/> as your preferred news source on Google</p><div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/> Add Now</p></div></div></div><p> Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. </p><p>The company is expected to raise about $254.9 million in gross proceeds from the offering. It has also granted underwriters a 30-day option to purchase an additional 2.12 million shares. </p><p>The shares are set to begin trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker &#34;SPTX&#34;, with the offering expected to close on May 4, 2026. Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and Stifel are serving as joint book-running managers for the deal. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

<p>Seaport Therapeutics, Inc. has priced its upsized IPO of 14.16 million shares at $18 each, raising approximately $254.9 million. The shares will trade on the Nasdaq under the ticker "SPTX" starting May 1, 2026, with the offering closing on May 4, 2026. Underwriters have a 30-day option to purchase an additional 2.12 million shares, with Goldman Sachs, J.P. Morgan, and others as joint book-running managers.</p>

rttnews

iShares Biotechnology ETF

Proshares UltraShort Nasdaq Biotech

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Minsheng Royal CSI Biotechnology Theme ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

Nasdaq

Goldman Sachs

JPMorgan Chase

Citigroup

Stifel Financial

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each